Research Area
Metabolic Research
Metabolic peptide research spans the incretin system, growth-hormone secretagogues with downstream lipolytic activity, and small-molecule modulators of mitochondrial fatty-acid oxidation. The compounds in this hub are the most heavily studied class in current peptide literature.
Research Use Only. All content on this page is for educational purposes. Compounds discussed are supplied solely for laboratory and research use. Where the active ingredient overlaps with an approved medication of the same name, the research compound is not the same product as any FDA-approved formulation containing the same active ingredient.
The incretin family — GLP-1 mono-agonists, GLP-1/GIP dual agonists, and GLP-1/GIP/glucagon triagonists — share a common pharmacophore family but differ markedly in receptor selectivity and pharmacokinetics. Each subsequent generation of incretin compound has expanded receptor coverage, with research increasingly focused on the relative contribution of GIP and glucagon receptor activation to the overall metabolic profile.
Adjacent to the incretins, growth-hormone secretagogues (tesamorelin, sermorelin, CJC-1295, ipamorelin) and the AOD-9604 fragment are studied for their effects on lipolysis and visceral adipose distribution. Small-molecule modulators of mitochondrial metabolism — 5-Amino-1MQ, MOTS-c — represent a distinct mechanistic axis worth tracking separately.
Most metabolic compounds in this hub are reference standards for laboratory comparison work. Where the active ingredient overlaps with an approved medication of the same name, the research compound is supplied for in-vitro and analytical work only and is not the same product as any FDA-approved formulation containing the same INN.
Compounds in this area
GLP-1 SM: GLP-1 Receptor Agonist Research Overview
GLP-1 SM is a synthetic peptide research compound in the GLP-1 receptor agonist class. The compound is used in preclinical studies of incretin signaling, pancreatic beta cell function, and central appetite-regulating pathways. This page summarizes the published research literature on GLP-1 receptor agonist pharmacology and the laboratory models used.
Read research overview →
GLP-2 TRZ: Dual GLP-1/GIP Receptor Agonist Research Overview
GLP-2 TRZ is a synthetic peptide designed to simultaneously activate two incretin receptor systems: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). The compound belongs to the dual-agonist research class, conceptually positioned between single-receptor incretin agonists and tri-agonists like GLP-3 RT. This page summarizes the published preclinical research on dual incretin receptor pharmacology and the laboratory models used.
Read research overview →
GLP-3 RT: Tri-Agonist Incretin Research Peptide Overview
GLP-3 RT is a synthetic peptide engineered to simultaneously activate three metabolic receptor systems: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and the glucagon receptor. This page summarizes the published preclinical research surrounding tri-agonist incretin peptide design, structural chemistry, receptor pharmacology, and the laboratory models used to characterize compounds in this class. For research and educational reference only.
Read research overview →
Cagrilintide: Long-Acting Amylin Analog Research Overview
Cagrilintide is a synthetic peptide research compound engineered as a long-acting analog of the natural pancreatic hormone amylin. It is studied in preclinical research on the amylin/calcitonin receptor family and satiety signaling pathways. This page summarizes the published research on Cagrilintide's chemistry, receptor pharmacology, and laboratory applications.
Read research overview →
Tesamorelin: GHRH Analog Research Overview
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), specifically engineered with an N-terminal modification that distinguishes it from the native peptide. This page summarizes the published research literature on Tesamorelin's structural design, receptor pharmacology, and the preclinical laboratory models used to characterize compounds in the GHRH-analog class.
Read research overview →
Tesofensine: Monoamine Reuptake Inhibitor Research Overview
Tesofensine is a synthetic small molecule research compound that inhibits the reuptake of three monoamine neurotransmitters: norepinephrine, serotonin, and dopamine. Unlike the peptide compounds in much of this catalog, Tesofensine is a small molecule originally developed as a research tool for neurological disorder pharmacology, with later research interest in metabolic signaling effects. This page summarizes the published preclinical literature.
Read research overview →
AOD-9604: Growth Hormone C-Terminal Fragment Research Overview
AOD-9604 (Anti-Obesity Drug 9604) is a synthetic peptide representing residues 177-191 of growth hormone's C-terminal region, with a tyrosine modification to enhance stability. The compound was designed to capture the lipolytic signaling of full-length growth hormone in a smaller peptide. This page summarizes the published preclinical research.
Read research overview →
5-Amino-1MQ: NNMT Inhibitor Research Overview
5-Amino-1-methylquinolinium (5-Amino-1MQ) is a synthetic small molecule research compound that inhibits the enzyme nicotinamide N-methyltransferase (NNMT). NNMT methylates nicotinamide, removing it from the NAD+ salvage pathway. Inhibiting NNMT preserves nicotinamide for NAD+ synthesis, making 5-Amino-1MQ a research tool for studies of NAD+ metabolism. This page summarizes the published preclinical literature.
Read research overview →
MOTS-c: Mitochondrial-Derived Peptide Research Overview
MOTS-c (Mitochondrial Open Reading frame of the Twelve S rRNA-c) is a 16-amino acid peptide encoded within the mitochondrial 12S ribosomal RNA gene, making it one of a small class of known mitochondrial-derived peptides (MDPs). This page summarizes the published preclinical research on MOTS-c, its proposed mechanisms in metabolic signaling, and the laboratory models commonly used in MDP research.
Read research overview →
Related research areas
This page references compounds by their International Nonproprietary Name (INN) — the scientific designation used in PubMed and FDA literature. Brand-name medications are not referenced. All compounds are supplied as research-grade reference standards for laboratory and analytical use only.